Salarius Pharmaceuticals Revenue and Competitors

Houston, TX USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Salarius Pharmaceuticals's estimated annual revenue is currently $2.8M per year.(i)
  • Salarius Pharmaceuticals's estimated revenue per employee is $232,500

Employee Data

  • Salarius Pharmaceuticals has 12 Employees.(i)
  • Salarius Pharmaceuticals grew their employee count by -50% last year.

Salarius Pharmaceuticals's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CFOReveal Email/Phone
3
SVP, Clinical DevelopmentReveal Email/Phone
4
VP, Chemistry, Manufacturing and ControlReveal Email/Phone
5
Executive Director, CMCReveal Email/Phone
6
Director Targeted Protein Degradation DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-8%N/AN/A
#2
$14.9M96-6%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$1.6M100%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.8M1850%N/AN/A
#7
$7.4M48-2%N/AN/A
#8
$0.8M50%N/AN/A
#9
$1.6M100%N/AN/A
#10
$16.3M10562%N/AN/A
Add Company

What Is Salarius Pharmaceuticals?

Salarius Pharmaceuticals (NASDAQ: SLRX) is a clinical-stage oncology company targeting the epigenetic causes of cancers and is developing treatments for patients that need them the most. The company's lead candidate, Seclidemstat, is currently in clinical development for treating Ewing sarcoma, for which it has Orphan Drug designation and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration. Salarius believes that Seclidemstat is one of only two reversible inhibitors of the epigenetic modulator LSD1 currently in human trials, and that it could have potential for improved safety and efficacy compared to other LSD1-targeted therapies. Salarius is also developing Seclidemstat for a number of cancers with high unmet medical need, with an ongoing clinical study in Ewing sarcoma and a clinical study in advanced solid tumors, including prostate, breast and ovarian cancers. Salarius receives financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and is also the recipient of an $18.7 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT)

keywords:N/A

N/A

Total Funding

12

Number of Employees

$2.8M

Revenue (est)

-50%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.9M12-14%N/A
#2
$1M12N/AN/A
#3
$1.2M12N/AN/A
#4
$1M12N/AN/A
#5
$1M12N/AN/A